ARTICLE | Clinical News
Novuspharma begins Phase II with BBR 3464
June 21, 2001 7:00 AM UTC
Novuspharma (NMerc:NOV) began an open-label U.S. Phase II study of its BBR 3464 platinum compound in up to 50 chemotherapy-nave patients with advanced pancreatic cancer. Novuspharma has an exclusive l...